Skip to main content
Top
Published in: Globalization and Health 1/2016

Open Access 01-12-2016 | Research

Assessment of the scope and practice of evaluation among medical donation programs

Authors: Alisa M. Jenny, Meng Li, Elizabeth Ashbourne, Myron Aldrink, Christine Funk, Andy Stergachis

Published in: Globalization and Health | Issue 1/2016

Login to get access

Abstract

Background

Medical donation programs for drugs, other medical products, training and other supportive services can improve access to essential medicines in low- and middle-income countries (LMICs) and provide emergency and disaster relief. The scope and extent to which medical donation programs evaluate their impact on recipients and health systems is not well documented.

Methods

We conducted a survey of the member organizations of the Partnership for Quality Medical Donations (PQMD), a global alliance of non-profit and corporate organizations, to identify evaluations conducted in conjunction with donation programs.

Results

Twenty-five out of the 36 PQMD organizations that were members at the time of the survey participated in the study, for a response rate of 69 %. PQMD members provided information on 34 of their major medical donation programs. Half of the donation programs reported conducting trainings as a part of their donation program. Twenty-six (76 %) programs reported that they conduct routine monitoring of their donation programs. Less than 30 % of donation programs were evaluated for their impact on health. Lack of technical staff and lack of funding were reported as key barriers to conducting impact evaluations.

Conclusions

Member organizations of PQMD provide a broad range of medical donations, targeting a wide range of public health issues and events. While some level of monitoring and evaluation was conducted in nearly 80 % of the donation programs, a program’s impact was infrequently evaluated. Opportunities exist to develop consistent metrics for medical donation programs, develop a common framework for impact evaluations, and advocate for data collection and analysis plans that collect meaningful metrics.
Literature
1.
go back to reference Cameron A, Ewen M, Ross-Degnan D, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: A secondary analysis. Lancet. 2009;373:240–9.CrossRefPubMed Cameron A, Ewen M, Ross-Degnan D, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: A secondary analysis. Lancet. 2009;373:240–9.CrossRefPubMed
2.
go back to reference Cameron A, Roubos I, Ewen M, et al. Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bull World Health Organ. 2011;89:412–21.CrossRefPubMedPubMedCentral Cameron A, Roubos I, Ewen M, et al. Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bull World Health Organ. 2011;89:412–21.CrossRefPubMedPubMedCentral
3.
go back to reference van Mourik MS, Cameron A, Ewen M, et al. Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord. 2010;10:25.CrossRefPubMedPubMedCentral van Mourik MS, Cameron A, Ewen M, et al. Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord. 2010;10:25.CrossRefPubMedPubMedCentral
4.
go back to reference Babar ZU, Lessing C, Mace C, et al. The availability, pricing and affordability of three essential asthma medicines in 52 low- and middle-income countries. Pharmacoeconomics. 2013;31(11):1063–82.CrossRefPubMed Babar ZU, Lessing C, Mace C, et al. The availability, pricing and affordability of three essential asthma medicines in 52 low- and middle-income countries. Pharmacoeconomics. 2013;31(11):1063–82.CrossRefPubMed
5.
go back to reference Cameron A, Bansal A, Dua T, et al. Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries. Epilepsia. 2012;53(6):962–9.CrossRefPubMed Cameron A, Bansal A, Dua T, et al. Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries. Epilepsia. 2012;53(6):962–9.CrossRefPubMed
9.
go back to reference Hanson C, Weaver A, Zoerhoff KL, et al. Integrated implementation of programs targeting neglected tropical diseases through preventive chemotherapy: identifying best practices to roll Out programs at national scale. Am J Trop Med Hyg. 2012;86(3):508–13.CrossRefPubMedPubMedCentral Hanson C, Weaver A, Zoerhoff KL, et al. Integrated implementation of programs targeting neglected tropical diseases through preventive chemotherapy: identifying best practices to roll Out programs at national scale. Am J Trop Med Hyg. 2012;86(3):508–13.CrossRefPubMedPubMedCentral
11.
go back to reference Mahmood M, Riley K, Bennett D, et al. The supply of pharmaceuticals in humanitarian assistance missions: implications for military operations. Mil Med. 2011;176(8):852–7.CrossRefPubMed Mahmood M, Riley K, Bennett D, et al. The supply of pharmaceuticals in humanitarian assistance missions: implications for military operations. Mil Med. 2011;176(8):852–7.CrossRefPubMed
13.
go back to reference Autier P, Govindaraj R, Gray R, et al. Drug Donations in Post-Emergency Situations. Health, Nutrition and Population Discussion Paper. Washington, DC: The International Bank for Reconstruction and Development / The World Bank; 2002. Autier P, Govindaraj R, Gray R, et al. Drug Donations in Post-Emergency Situations. Health, Nutrition and Population Discussion Paper. Washington, DC: The International Bank for Reconstruction and Development / The World Bank; 2002.
14.
go back to reference Berckmans P, Dawans V, Schmets G, et al. Inappropriate drug donation practices in Bosnia and Herzegovina, 1992–1996. N Eng J Med. 1997;337:1842–45.CrossRef Berckmans P, Dawans V, Schmets G, et al. Inappropriate drug donation practices in Bosnia and Herzegovina, 1992–1996. N Eng J Med. 1997;337:1842–45.CrossRef
17.
go back to reference Ladner J, Besson MH, Rodrigues M, et al. Prevention of mother-to-child HIV transmission in resource-limited settings: assessment of 99 Viramune Donation Programmes in 34 countries, 2000–2011. BMC Public Health. 2013;13:470.CrossRefPubMedPubMedCentral Ladner J, Besson MH, Rodrigues M, et al. Prevention of mother-to-child HIV transmission in resource-limited settings: assessment of 99 Viramune Donation Programmes in 34 countries, 2000–2011. BMC Public Health. 2013;13:470.CrossRefPubMedPubMedCentral
18.
go back to reference Tekinturhan E, Audureau E, Tavolacci MP, et al. Improving access to care in low and middle-income countries: institutional factors related to enrollment and patient outcome in a cancer drug access program. BMC Health Serv Res. 2013;13:304.CrossRefPubMedPubMedCentral Tekinturhan E, Audureau E, Tavolacci MP, et al. Improving access to care in low and middle-income countries: institutional factors related to enrollment and patient outcome in a cancer drug access program. BMC Health Serv Res. 2013;13:304.CrossRefPubMedPubMedCentral
19.
go back to reference Gustavsen KM, Bradley MH, Wright AL. GlaxoSmithKline and Merck: private-sector collaboration for the elimination of lymphatic filariasis. Ann Trop Med Parasitol. 2009;103 Suppl 1:S11–5.CrossRefPubMed Gustavsen KM, Bradley MH, Wright AL. GlaxoSmithKline and Merck: private-sector collaboration for the elimination of lymphatic filariasis. Ann Trop Med Parasitol. 2009;103 Suppl 1:S11–5.CrossRefPubMed
20.
go back to reference Boatin B. The Onchocerciasis Control Programme in West Africa (OCP). Ann Trop Med Parasitol. 2008;102 Suppl 1:13–7.CrossRefPubMed Boatin B. The Onchocerciasis Control Programme in West Africa (OCP). Ann Trop Med Parasitol. 2008;102 Suppl 1:13–7.CrossRefPubMed
21.
go back to reference Wertheimer AI, Santella TM, Lauver HJ. Successful public/private donation programs: a review of the Diflucan Partnership Program in South Africa. J Int Assoc Physicians AIDS Care (JIAPAC). 2004;3(3):74–9. 84–5.CrossRef Wertheimer AI, Santella TM, Lauver HJ. Successful public/private donation programs: a review of the Diflucan Partnership Program in South Africa. J Int Assoc Physicians AIDS Care (JIAPAC). 2004;3(3):74–9. 84–5.CrossRef
22.
go back to reference Peters D, Phillips T. Mectizan donation program: evaluation of a public-private partnership. Tropical Med International Health. 2004;9:4–15.CrossRef Peters D, Phillips T. Mectizan donation program: evaluation of a public-private partnership. Tropical Med International Health. 2004;9:4–15.CrossRef
23.
go back to reference Burnham G, Mebrahtu T. The delivery of ivermectin (Mectizan). Tropical Med Int Health. 2004;9:26–44.CrossRef Burnham G, Mebrahtu T. The delivery of ivermectin (Mectizan). Tropical Med Int Health. 2004;9:26–44.CrossRef
24.
go back to reference Paluzzi JE. “Dualities of interest”: the inter-organizational relationships between disease-specific nonprofits and the pharmaceutical industry. Int J Health Serv. 2012;42(2):323–39.CrossRefPubMed Paluzzi JE. “Dualities of interest”: the inter-organizational relationships between disease-specific nonprofits and the pharmaceutical industry. Int J Health Serv. 2012;42(2):323–39.CrossRefPubMed
25.
go back to reference Bero L, Carson B, Moller H, et al. To give is better than to receive: compliance with WHO guidelines for drug donations during 2000–2008. Bull World Health Organ. 2010;88(12):922–9.CrossRefPubMedPubMedCentral Bero L, Carson B, Moller H, et al. To give is better than to receive: compliance with WHO guidelines for drug donations during 2000–2008. Bull World Health Organ. 2010;88(12):922–9.CrossRefPubMedPubMedCentral
26.
go back to reference Turner HC, Walker M, Churcher TS, et al. Reaching the London declaration on neglected tropical diseases goals for onchocerciasis: an economic evaluation of increasing the frequency of ivermectin treatment in Africa. Clin Infect Dis. 2014;59(7):923–32.CrossRefPubMedPubMedCentral Turner HC, Walker M, Churcher TS, et al. Reaching the London declaration on neglected tropical diseases goals for onchocerciasis: an economic evaluation of increasing the frequency of ivermectin treatment in Africa. Clin Infect Dis. 2014;59(7):923–32.CrossRefPubMedPubMedCentral
27.
go back to reference Turner HC, Walker M, Churcher TS, et al. Modelling the impact of ivermectin on River Blindness and its burden of morbidity and mortality in African Savannah: EpiOncho projections. Parasit Vectors. 2014;7:241.CrossRefPubMedPubMedCentral Turner HC, Walker M, Churcher TS, et al. Modelling the impact of ivermectin on River Blindness and its burden of morbidity and mortality in African Savannah: EpiOncho projections. Parasit Vectors. 2014;7:241.CrossRefPubMedPubMedCentral
28.
go back to reference Waters HR, Rehwinkel JA, Burnham G, et al. Economic evaluation of Mectizan distribution. Trop Med Int Health. 2004;9(4):A16–25.CrossRefPubMed Waters HR, Rehwinkel JA, Burnham G, et al. Economic evaluation of Mectizan distribution. Trop Med Int Health. 2004;9(4):A16–25.CrossRefPubMed
29.
go back to reference Coffeng LE, Stolk WA, Hoerauf A, et al. Elimination of African onchocerciasis: modeling the impact of increasing the frequency of ivermectin mass treatment. PLoS One. 2014;9(12):e115886.CrossRefPubMedPubMedCentral Coffeng LE, Stolk WA, Hoerauf A, et al. Elimination of African onchocerciasis: modeling the impact of increasing the frequency of ivermectin mass treatment. PLoS One. 2014;9(12):e115886.CrossRefPubMedPubMedCentral
Metadata
Title
Assessment of the scope and practice of evaluation among medical donation programs
Authors
Alisa M. Jenny
Meng Li
Elizabeth Ashbourne
Myron Aldrink
Christine Funk
Andy Stergachis
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Globalization and Health / Issue 1/2016
Electronic ISSN: 1744-8603
DOI
https://doi.org/10.1186/s12992-016-0210-8

Other articles of this Issue 1/2016

Globalization and Health 1/2016 Go to the issue